Astrid Zimmermann
Frankfurter Str. 250
Darmstadt, HE 64293, Germany
Darmstadt, HE 64293, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Journal: Clinical pharmacology and therapeutics
Published: December 18, 2024
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 26, 2024
PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells.
Journal: Cell death discovery
Published: August 09, 2024
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
Journal: International journal of molecular sciences
Published: March 25, 2024
Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Journal: EMBO molecular medicine
Published: February 17, 2024
Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.
Journal: British journal of cancer
Published: January 19, 2024
DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models.
Journal: Cancers
Published: November 27, 2023
Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors.
Journal: Cancer research
Published: November 16, 2023
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs.
Journal: Molecular cancer therapeutics
Published: June 25, 2023
ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Journal: EMBO molecular medicine
Published: December 16, 2022
Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Journal: Molecular cancer therapeutics
Published: October 18, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
Journal: Cancer research
Published: December 21, 2021
Last Updated: 09/26/2026